Quinidine Calcium-channel blockers

Procainamide, quinidine, quinine, disopyramide, phenytoin, and (i-adrenergic blockers, calcium channel blockers... 

Drugs that may affect amiodarone include hydantoins, cholestyramine, fluoroquinolones, rifamycins, ritonavir, and cimetidine. Drugs that may be affected by amiodarone include anticoagulants, beta-blockers, calcium channel blockers, cyclosporine, dextromethorphan, digoxin, disopyramide, fentanyl, flecainide, hydantoins, lidocaine, methotrexate, procainamide, quinidine, and theophylline. Drug/Lab test interactions Amiodarone alters the results of thyroid function tests, causing an increase in serum T4 and serum reverse T3 levels and a decline in... 

Drugs affected by voriconazole include the following benzodiazepines, calcium channel blockers, cisapride, coumarin anticoagulants, cyclosporine, ergot alkaloids, HMG-CoA reductase inhibitors, NNRTIs, phenytoin, protease inhibitors, pimozide, proton pump inhibitors, quinidine, prednisolone, rifabutin, sirolimus, sulfonylureas, tacrolimus, vinca alkaloids. 

Drugs that might be affected by lopinavir/ritonavir include ergot derivatives, oral contraceptives, antiarrhythmics, HMG-CoA reductase inhibitors, HIV protease inhibitors, atovaquone, calcium channel blockers, ketoconazole, itraconazole, pimozide, cisapride, clarithromycin, disulfiram, metronidazole, immunosuppressants, midazolam, triazolam, narcotic analgesics, rifabutin and rifabutin metabolite, sildenafil, warfarin, bupropion, clozapine, desipramine, piroxicam, quinidine, theophylline, and zolpidem. 

Drugs that may be affected by delavirdine include the following Clarithromycin, indinavir, amprenavir, benzodiazepines, cisapride, dihydropyridine calcium channel blockers, ergot derivatives, quinidine, sildenafil, warfarin, saquinavir, and didanosine. 

Drugs that may be affected by fosamprenavir include the following Amiodarone, amitriptyline, benzodiazepines, calcium channel blockers, cisapride, contraceptives (oral), cyclosporine, ergot derivatives, HMG-CoA reductase inhibitors, imipramine, itraconazole, ketoconazole, lidocaine (systemic), methadone, pimozide, quinidine, rifabutin, sildenafil, tacrolimus, vardenafil, warfarin. 

During the last decades several drugs and compounds have been identified that to different degrees are able to overcome MDR so that the cells resemble sensitive cells in their chemosensitivity. These drugs mainly include catamphiphilic, membrane-active compounds and belong to various classes of drugs such as calcium channel blockers (verapamil), neuroleptics (flupentixol), anesthetics, antimalarial drugs (quinidine), antiarrhythmics (amiodarone), and many other compounds. Reviews were recently published [61, 157]. 

Quinidine overdose should be treated with symptomatic and supportive therapy. Quinidine should be used with caution when coadministering with calcium channel blockers, diuretics, beta-blockers, antibacterials, antifungals, and antiarrhythmics.97... 

Patients should be advised to rest and to avoid extreme heat. They should be warned that symptoms may be aggravated by illness, stress, malnutrition, pain, or surgery. Various drugs have been shown to worsen symptoms of myasthenia gravis. These include the aminoglycoside antibiotics such as tobramycin, gentamicin, and neomycin tetracyclines such as doxycycline and minocycline class 1 antiarrhythmics such as lidocaine, quinidine, and procainamide magnesium in calcium and multivitamin supplements beta-blockers such as timolol and propranolol calcium channel blockers such as verapamil and penicillamine. 

Clinically important, potentially hazardous interactions with acetazolamide, aminoglycosides, anticholinesterases, bambuterol, calcium channel blockers, chloroquine, chlorpromazine, clindamycin, d-pencillamine, ecothiophate iodine, enflurane, furosemide, halothane, hexomethonium, isoflurane, ketamine, lidocaine, lincomycin, lithium salts, magnesium salts, mannitol, MAO inhibitors, organophosphates, pancuronium, phenytoin, polymyxins, procainamide, quinidine, sevoflurane, spectinomycin, tetracyclines... 

Clinically important, potentially hazardous interactions with calcium channel blockers, cyclosporine, methotrexate, quinidine, trimetrexate... 

A reduction in the labeling yield of RBC has been reported for heparin, tin-over-load, aluminum, prazocin, methyldopa, hydralazine, digoxin, quinidine, jff-adrenergic blockers, (e.g., propanolol), calcium channel blockers (e.g., verapamil), nitrates (e.g., nitroglycerin), doxorubicin, iodinated contrast agents, and Teflon tubing (catheter) (Hladik et al. 1987). 

Barbiturates, especially phenobarbital Azoles, calcium channel blockers, propranolol, quinidine, steroids, wailarin, and many other drugs metabolized in the liver Increased deararx of the affected drugs due to enzyme induction, possibly leading to decreases in drug effectiveness... 

Adverse reactions to somatostatin analogues have been extensively reported. The asymptomatic effects have been reviewed [23, 34 ]. There are asymptomatic gallstones in 20-40, bradycardia in up to 25%, and conduction abnormalities in 10%. Somatostatin analogues may alter the absorption of other drugs, especially oral hypoglycemic agents, p blockers, calcium channel blockers, and dclosporin, while effects on CYP isoenzymes may alter concentrations of quinidine, terfenadine, and warfarin. Somatostatin analogues... 

Digoxin toxicity use of quinidine, procainamide, beta blockers, calcium channel blockers, or amiodarona nel blockers, and beta blockers. 

Increased risk of toxicity with drugs that alter serum electrolytes (potassium -depleting diuretics, corticosteroids, thiazide and loop diuretics, amphotericin B, quinidine, amiodarone). Blockers of p adrenergic receptors, calcium channels, or acetylcholinesterase increase risk of complete AV block. Drugs which alter Gl absorption may alter bioavallabillty. 

---